Polycystic Kidney Diseases Therapeutics Market Report 2024: Comprehensive Insights About 8+ Companies and 10+ Pipeline Drugs [Yahoo! Finance]
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences [Yahoo! Finance]
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates